Sequent Scientific Ltd.

NSE: SEQUENT | BSE: 512529 | ISIN: INE807F01027 |Industry: Pharmaceuticals
|Expensive Star
154.45 0.85 (0.55%)
NSE Oct 23, 2020 15:31 PM
Volume: 698.3K

Sequent Scientific Ltd.    
13 Aug 2018
Nirmal Bang Institutional
Regulatory Changes And Adverse Forex Movement Dampens Momentum Sequent Scientific or SSL's revenues at Rs2,369mn in 1QFY19 were in line with our estimate. EBITDA at Rs250mn was up 70% YoY and down 19% QoQ as regulatory changes in Turkey impacted performance. Turkey, which is the single largest geography for SSL's formulations business, witnessed an adverse impact of new regulations to ensure judicious use of antimicrobials. This led to a decline in primary sales. SSL is the third-largest player in Turkey with a 10% market share, and on QoQ basis the sales declined almost 40% from Rs 400mn to Rs 243mn. The company expects sales in Turkey to be back to normal by the end of FY19. Animal API business, which accounts for about 25% of its sales, reported strong growth (4% QoQ and 12.3%...
Sequent Scientific L.. has an average target of 146.33 from 3 brokers.
More from Sequent Scientific Ltd.